Page 3 - Immuron Ltd News Today

Globally integrated biopharmaceuticals company Immuron Ltd (NASDAQ:IMRN, ASX:IMC) has had a bumper year for its over-the-counter gastrointestinal and...

The Board of Directors of Immuron Ltd (NASDAQ:IMRN, ASX:IMC) has given the green light for the company to proceed with IMM-529 cGMP manufacturing for the...

Immuron Ltd (NASDAQ:IMRN, ASX:IMC) has received US Army Medical Research and Development Command (USAMRDC) Office of Human and Animal Research Oversight...

The ASX drove higher today, with the S&P/ASX200 gaining 52.50 points or 0.73% to 7,272.50 and crossing above its 125-day moving average. Over the last five...

Immuron Ltd (NASDAQ:IMRN, ASX:IMC), an immunotherapy-focused biopharmaceutical company based in Australia, is readying to proceed with clinical evaluation...

By Chris Wack Immuron Ltd. said Monday that the U.S. Naval Medical Research Center has received approval from the U.S. Food and Drug Administration to proceed with the clinical evaluation of a... | May 8, 2023

The U.S.-listed shares of Immuron Ltd. IMRN powered up 66.3% toward a one-year high in premarket trading Monday, after the Australia-based biopharmaceutical…

By Chris Wack Immuron Ltd. shares were up 45% to $2.71 after the company said that the U.S. Naval Medical Research Center has received approval from the U.S. Food and Drug Administration to... | May 8, 2023

The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s...

Immuron Ltd (NASDAQ:IMRN, ASX:IMC) CEO Steven Lydeamore is a numbers guy. You can tell by the thoughtful, considered way he reflects on his experience that...